发明名称 |
Methods for treatment of alport syndrome |
摘要 |
Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport Syndrome. In certain embodiments, a modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport Syndrome. |
申请公布号 |
US9359609(B2) |
申请公布日期 |
2016.06.07 |
申请号 |
US201514677387 |
申请日期 |
2015.04.02 |
申请人 |
Regulus Therapeutics Inc. |
发明人 |
Duffield Jeremy;Bhat Balkrishen;MacKenna Deidre |
分类号 |
A61K31/70;C07H21/02;C07H21/04;C12N15/113;A61K45/06;A61K31/7088;C12Q1/68 |
主分类号 |
A61K31/70 |
代理机构 |
McNeill Baur PLLC |
代理人 |
McNeill Baur PLLC |
主权项 |
1. A method of treating Alport Syndrome comprising administering to a subject having or suspected of having Alport Syndrome a pharmaceutical composition comprising a therapeutically effective amount of a modified oligonucleotide consisting of 19 linked nucleosides and having the structure 5′-AECSATCSAGTCSTGAUSAAGCSTAE-3′ (SEQ ID NO: 3), where nucleosides not followed by a subscript are β-D-deoxyribonucleosides; nucleosides followed by a subscript “E” are 2′-MOE nucleosides; nucleosides followed by a subscript “S” are S-cEt nucleosides, and each internucleoside linkage is a phosphorothioate internucleoside linkage. |
地址 |
San Diego CA US |